Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapy options and a poor prognosis.
• The lack of effective treatments necessitates the development of novel therapeutic strategies for TNBC.
• Targeting specific molecular pathways offers a potential avenue for improving patient outcomes.

Purpose of the Study:

• To synthesize and evaluate a novel dual-action compound combining quinone and cannabinoid pharmacophores for TNBC treatment.
• To assess the compound's selectivity for the nonpsychotropic CB2 cannabinoid receptor.
• To determine the compound's in vivo antitumor efficacy and safety profile in TNBC models.

Main Methods:

• Synthesis of a series of chromenopyrazolediones, with compound 10 identified as a lead candidate.
• In vitro evaluation of compound 10's efficacy in inducing death of human TNBC cell lines.
• In vivo assessment of compound 10's antitumor activity and toxicity in relevant models.
• Investigation of the compound's mechanism of action, including CB2 receptor activation and oxidative stress induction.

Main Results:

• Compound 10 demonstrated potent antitumor activity against human TNBC cell lines.
• The compound exhibited full selectivity for the nonpsychotropic CB2 cannabinoid receptor.
• Compound 10 induced cancer cell death through apoptosis via CB2 receptor activation and oxidative stress.
• No cytotoxicity was observed in noncancerous human mammary epithelial cells or significant toxicity in vivo.

Conclusions:

• Compound 10 represents a promising new therapeutic agent for triple-negative breast cancer.
• The dual quinone/cannabinoid approach, targeting CB2 receptors and inducing oxidative stress, is effective against TNBC.
• The compound's selectivity and favorable safety profile suggest its potential as a novel therapeutic tool for TNBC management.